Insmed Incorporated - Common Stock (INSM) is currently showing a bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently mixed earnings tone.
HEADLINE TAKE: Higher-value headlines lean meaningfully positive, with stronger signals around growth, upgrades, guidance, or demand.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor
NEWS SCORE
70/100
Bullish
Bearish
Neutral
Bullish
Earnings Tone
78
Good based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$109.81
Trend Context
Mixed / range
Latest briefing
What's happening with INSM
seekingalpha.com14 Jul 2026
Carillon Eagle Mid Cap Growth Fund Q2 2026 Portfolio Review
Carillon Eagle Mid Cap Growth Fund stocks delivered solid results in the second quarter. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions. Top securities in the quarter were Datadog, Marvell, Vertiv, Teradyne and Macom Technology Solutions.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com25 Jun 2026
EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
Hannover, Germany, June 25, 2026 (GLOBE NEWSWIRE) -- EMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis —Long-Term, Open-Label Study to Enroll Approximately 3,000 Patients Across Europe—
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com23 Jun 2026
Insmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
BRIDGEWATER, N.J., June 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective today.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
etftrends.com
22 Jun 2026
The Qs Shift Gears: Nasdaq 100 Rebalances While SpaceX Looms
